The Japanese Society of Thyroid Pathology and the Japan Association of Endocrine Surgeons developed the eighth edition of the General Rules for the Description of Thyroid Cancer (GRDTC) in December 2019. This article describes the pathological diagnosis of the GRDTC, which has been improved through repeated revisions based on the experience of Japanese pathologists and translated into English to introduce the Japanese diagnostic standard to foreign countries. In this edition of the GRDTC, the histopathological classification and descriptions differ in some respects from those of the fourth edition of the World Health Organization (WHO) classification as revised in 2017. For example, the GRDTC does not adopt the concept of borderline lesions (FT-UMP, WDT-UMP, and NIFTP) of the WHO, taking into consideration the popular histological criteria accepted by Japanese pathologists. The cytological reporting system of the GRDTC was partly modified from the Bethesda system in 2015. It has an additional cyst fluid category separated from the unsatisfactory category that has been demonstrated to be useful in Japan. This translated edition makes it easy to submit Japanese clinicopathological studies of thyroid tumors in an international journal. We also wish to contribute to the improvement, standardization, and globalization of the pathological diagnosis of thyroid tumors.

日本甲状腺病理学会和日本内分泌外科学会于 2019 年 12 月制定了第 8 版甲状腺癌描述通则（GRDTC）。本文描述了 GRDTC 的病理诊断，经过反复改进根据日本病理学家的经验进行修订并翻译成英文，将日本的诊断标准介绍给国外。在本版 GRDTC 中，组织病理学分类和描述在某些方面与 2017 年修订的世界卫生组织（WHO）第四版分类有所不同。例如，GRDTC 不采用边界病变的概念。 WHO 的 FT-UMP、WDT-UMP 和 NIFTP），考虑到日本病理学家接受的流行组织学标准。GRDTC 的细胞学报告系统在 2015 年对 Bethesda 系统进行了部分修改。它有一个额外的囊液类别，与已证明在日本有用的不满意类别分开。该翻译版本便于在国际期刊上提交日本甲状腺肿瘤临床病理学研究。我们也希望为甲状腺肿瘤病理诊断的改进、标准化和全球化做出贡献。该翻译版本便于在国际期刊上提交日本甲状腺肿瘤临床病理学研究。我们也希望为甲状腺肿瘤病理诊断的改进、标准化和全球化做出贡献。该翻译版本便于在国际期刊上提交日本甲状腺肿瘤临床病理学研究。我们也希望为甲状腺肿瘤病理诊断的改进、标准化和全球化做出贡献。